I come from Tainan, Taiwan and received my Ph.D from National Taiwan University. I joined Roberto’s Lab to extend my post-doc training in cancer immunotherapy since 2015. Since ALK can be targeted by the immune system, we reasoned that immunotherapy could represent a novel approach to treat ALK-positive tumor cells. The goal of my project is to find new ways to exploit the ability of the immune system to identify and kill tumors. The unique biological properties of ALK provide the opportunity to test chimeric antigen receptors (CARs) also in combination with ALK inhibitors or the ALK cancer vaccine we recently developed. The other project is to investigate the underlying molecular mechanism by which chromosomal translocation happens to induce EML4-ALK rearrangement in lung cancer.